Lithium research continues to yield benefits for treatment of bipolar disorder
To those familiar with the properties of lithium, it was no surprise that John Cade's seminal article1 was, in 2004, the most cited in the history of the Journal, and was aptly described as a jewel in the crown.2 After all, lithium has long had royal status in clinical practice guidelines and is very much in its element in blue blood.3 Hence, the fact that another decade later Cade's groundbreaking study has retained regal standing in the archives of the Journal is to be expected. But perhaps what is truly remarkable is the fact that lithium has recently strengthened its clinical profile in the pharmacological armamentarium presently used to treat bipolar disorder.4 This resurgence of interest reflects lithium's enduring efficacy — put bluntly, it works. Lithium is arguably the best agent for the most critical phase of bipolar disorder, long-term prophylaxis, and as such it is the only true mood stabiliser.5 Boosting its profile further, lithium is both antisuicidal6 and neuroprotective.4
Unfortunately, lithium can be toxic, acutely so at high doses, but also at low doses when administered chronically, although the true risks have been somewhat exaggerated.7 As the only antimanic agent, it would be useful to understand its mechanism of action, so as to target those patients most likely to respond and to develop mimetics that can replicate lithium's specific actions without reproducing its tolerability problems. Recent studies have identified genetic variations associated with lithium response,8 and potential lithium-like molecules are undergoing development.9 These ambitious endeavours aim to advance the treatment of bipolar disorder and, in doing so, will provide more robust means for defining the illness and equating diagnoses to disease. A lithium-responsive and lithium-defined subtype of bipolar disorder representing a biologically anchored phenotype could be called Cade's disease.10 Alas, although this would be a tremendous acknowledgement, perhaps the eponym would be better suited to describing the remedy that he discovered.
Provenance: Commissioned; not externally peer reviewed.
- 1. Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2: 349-352.
- 2. Gregory AT. Jewels in the crown: The Medical Journal of Australia's 10 most-cited articles. Med J Aust 2004; 181: 9-12. <MJA full text>
- 3. Malhi GS. The king is dead, long live the king! The restoration of BALANCE. Bipolar Disord 2010; 12: 681-684.
- 4. Malhi GS. [Lithium: an element of blue blood?] [French] Ann Med Psychol (Paris) 2014; 172: 155-157.
- 5. Goodwin GM, Malhi GS. What is a mood stabilizer? Psychol Med 2007; 37: 609-614.
- 6. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346: f3646.
- 7. Mcknight R, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379: 721-728.
- 8. Chen CH, Lee CS, Lee MT, et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med 2014; 370: 119-128.
- 9. Singh N, Halliday AC, Thomas JM, et al. A safe lithium mimetic for bipolar disorder. Nat Commun 2013; 4: 1332.
- 10. Ghaemi SN, Ko JY, Goodwin FK. “Cade's disease” and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002; 47: 125-134.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.